| Primary |
| Renal Cell Carcinoma |
23.5% |
| Hypertension |
12.4% |
| Neoplasm |
11.2% |
| Sarcoma |
9.1% |
| Pain |
6.0% |
| Non-small Cell Lung Cancer |
5.6% |
| Metastatic Renal Cell Carcinoma |
4.0% |
| Ovarian Cancer |
3.9% |
| Nausea |
3.7% |
| Neoplasm Malignant |
3.3% |
| Prophylaxis |
2.8% |
| Depression |
2.0% |
| Hypothyroidism |
1.9% |
| Breast Cancer |
1.7% |
| Constipation |
1.7% |
| Malignant Neoplasm Progression |
1.6% |
| Diabetes Mellitus |
1.6% |
| Leiomyosarcoma |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Supplementation Therapy |
1.2% |
|
| Pyrexia |
13.8% |
| Vomiting |
9.3% |
| Pulmonary Embolism |
8.7% |
| Anaemia |
8.0% |
| Febrile Neutropenia |
5.3% |
| Renal Failure |
5.1% |
| Renal Failure Acute |
4.9% |
| Dyspnoea |
4.4% |
| Death |
4.0% |
| Dehydration |
4.0% |
| Gamma-glutamyltransferase Increased |
4.0% |
| Deep Vein Thrombosis |
3.6% |
| Ileus |
3.6% |
| Pneumonia |
3.6% |
| Thrombocytopenia |
3.6% |
| Disease Progression |
2.9% |
| General Physical Health Deterioration |
2.9% |
| Pneumothorax |
2.9% |
| Urinary Tract Infection |
2.9% |
| Sepsis |
2.7% |
|
| Secondary |
| Malignant Glioma |
14.1% |
| Neoplasm |
13.2% |
| Renal Cell Carcinoma |
11.4% |
| Colorectal Cancer Metastatic |
7.9% |
| Colorectal Cancer |
7.7% |
| Metastatic Renal Cell Carcinoma |
6.7% |
| Hypertension |
5.5% |
| Epilepsy |
4.5% |
| Pain |
4.5% |
| Neoplasm Malignant |
3.7% |
| Cervix Carcinoma |
3.5% |
| Breast Cancer Metastatic |
2.8% |
| Sarcoma |
2.6% |
| Headache |
2.2% |
| Female Reproductive Neoplasm |
1.8% |
| Ovarian Cancer |
1.8% |
| Breast Cancer |
1.6% |
| Phaeochromocytoma |
1.6% |
| Prophylaxis |
1.6% |
| Rectal Cancer |
1.6% |
|
| Vomiting |
23.6% |
| Pyrexia |
9.3% |
| Pneumonia |
5.7% |
| Respiratory Failure |
5.7% |
| Thrombocytopenia |
5.7% |
| Ejection Fraction Decreased |
4.3% |
| Muscle Spasms |
4.3% |
| Anaemia |
3.6% |
| Diarrhoea |
3.6% |
| Haemorrhage |
3.6% |
| Hepatitis Toxic |
3.6% |
| Intermittent Claudication |
3.6% |
| Musculoskeletal Pain |
3.6% |
| Abdominal Abscess |
2.9% |
| Alanine Aminotransferase Increased |
2.9% |
| General Physical Health Deterioration |
2.9% |
| Hepatic Enzyme Increased |
2.9% |
| Hepatotoxicity |
2.9% |
| Pulmonary Embolism |
2.9% |
| Syncope |
2.9% |
|
| Concomitant |
| Metastatic Renal Cell Carcinoma |
22.2% |
| Renal Cell Carcinoma |
19.4% |
| Neoplasm Malignant |
11.1% |
| Lung Neoplasm Malignant |
8.3% |
| Neoplasm |
8.3% |
| Prophylaxis |
8.3% |
| Rectal Cancer |
8.3% |
| Bladder Cancer |
5.6% |
| Product Used For Unknown Indication |
2.8% |
| Renal Cancer |
2.8% |
| Renal Cancer Metastatic |
2.8% |
|
| Death |
13.0% |
| Haematuria |
8.7% |
| Treatment Noncompliance |
8.7% |
| Bone Pain |
4.3% |
| Diarrhoea |
4.3% |
| Diffuse Alveolar Damage |
4.3% |
| Dry Skin |
4.3% |
| Feeling Hot |
4.3% |
| Hypertension |
4.3% |
| Memory Impairment |
4.3% |
| Mental Status Changes |
4.3% |
| Myocardial Infarction |
4.3% |
| Neoplasm Progression |
4.3% |
| Pallor |
4.3% |
| Perineal Infection |
4.3% |
| Pneumonia |
4.3% |
| Spinal Compression Fracture |
4.3% |
| Swollen Tongue |
4.3% |
| Tongue Discolouration |
4.3% |
|
| Interacting |
| Neoplasm |
70.0% |
| Enzyme Inhibition |
30.0% |
|
| Drug Interaction |
30.0% |
| Hypertension |
10.0% |
| Hypoalbuminaemia |
10.0% |
| Hypokalaemia |
10.0% |
| Hypothyroidism |
10.0% |
| Lipase Increased |
10.0% |
| Lymphopenia |
10.0% |
| Vomiting |
10.0% |
|
